1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
0 |
| Hold |
0 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | 2023 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -3.49M | 76.49% |
| EBITDA | -3.49M | 35.74% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.25M |
Number of shares | 41.71K |
52-week high/low | €204.02 - €54.45 |
| Dividends | No |
Beta | 0.08 |
P/E ratio | 21.52 |
PEG ratio | 0.06 |
P/B ratio | 1.49 |
P/S ratio | 70.26 |
Company profile
Orphazyme A/S hat keine nennenswerte Geschäftstätigkeit. Zuvor war das Unternehmen in der Entwicklung von Therapien für die Behandlung seltener neurodegenerativer Erkrankungen tätig. Das Unternehmen wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in Kopenhagen, Dänemark.
| Name | Orphazyme Aktie |
| CEO | Jakob Færch Bendtsen |
| Headquarters | Copenhagen,
Denmark |
| Website | |
| IPO | 07/16/2019 |
| Employees | 1 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Copenhagen | ORPHA.CO |
Frankfurt | 1TB0.F |
London | 0CUM.L |
München | 1TB0.MU |
Düsseldorf | 1TB0.DU |
Discover assets
Shareholders of Orphazyme Aktie also invest in the following assets
